Saltar al contenido
PivotalWire
Domingo 22 nov 2026SEC · NASDAQ biomédico

Calendario›REGN›REGN2477 · LUMINA-1

REGN2477 · LUMINA-1

Ensayo de REGENERON PHARMACEUTICALS, INC. en Fibrodysplasia Ossificans Progressiva (del registro, en inglés).

Fase
Fase 2
Estado
Completado
Participantes
44
previstos
Centros
11
Fin del objetivo primario
sep 2019
fecha real

Título oficial en el registro (en inglés): A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en feb 2018.

De principio a fin

  1. Empieza el ensayo (feb 2018)
  2. Lectura de resultados sep 2019 (real)
  3. Hoy

Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.

Qué mide

Period 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs (del registro, en inglés) (hasta la semana 28)

Qué se prueba

Se mide si el fármaco del estudio, frente a placebo, cambia la osificación heterotópica en pacientes con FOP.

Lo que dice el documentoPrimary efficacy objective of the study is to assess the effect of REGN2477 versus placebo on the change from baseline in heterotopic ossification (HO) in patients with FOP, as determined by 18-NaF uptake in HO lesions by positron emission tomography (PET) and in total volume of HO lesions by computed tomography (CT).

Traducción automática (claude-haiku-5-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis is a three period study design consisting of a 6-month, randomized, double-blind placebo-controlled treatment (period 1) followed by a 6-month, open-label treatment (period 2) and a follow-up treatment period (period 3). Primary safety objective of the study is to assess the safety and tolerability of REGN2477 in male and female patients with fibrodysplasia ossificans progressiva (FOP). Primary efficacy objective of the study is to assess the effect of REGN2477 versus placebo on the change from baseline in heterotopic ossification (HO) in patients with FOP, as determined by 18-NaF uptake in HO lesions by positron emission tomography (PET) and in total volume of HO lesions by computed tomography (CT). Key Secondary objectives are: * To compare the effect of REGN2477 versus placebo on pain due to FOP, as measured by the area under the curve (AUC) for pain based on daily pain numeric rating scale (NRS) scores * To assess the effect of REGN2477 versus placebo on the change from baseline in HO, as determined by the number of new HO lesions identified by 18F-NaF PET or by CT * To assess the effect of REGN2477 versus placebo on the change from baseline in 18F-NaF standardized uptake value maximum (SUVmax) of individual active HO site(s) by PET * To assess the effect of REGN2477, between week 28 and week 56, on the number, activity, and volume of HO lesions identified by 18F-NaF PET or by CT in patients who switch from placebo to REGN2477 at week 28 versus the same patients between baseline and week 28 * To assess the effect of REGN2477 versus placebo on the change from baseline in biochemical markers of bone formation * To characterize the concentrations of total activin A at baseline and over time following the first dose of study drug * To characterize the concentration-time profile (pharmacokinetics [PK]) of REGN2477 in patients with FOP * To assess the immunogenicity of REGN2477

Sigue a REGN y recibe cada mañana en tu correo lo que haya presentado ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Más ensayos de REGN

EnsayoFaseEstadoLectura de resultados
cemiplimabFase 2En marcha, sin reclutarmar 2025 (real)
Pozelimab + Cemdisiran · NIMBLEFase 3En marcha, sin reclutarjul 2025 (real)
Garetosmab · OPTIMAFase 3En marcha, sin reclutarjul 2025 (real)
Aflibercept 8 mg · ELARAFase 3En marcha, sin reclutarago 2025 (real)
Dupilumab · ENGAGEFase 2En marcha, sin reclutarfeb 2026 (real)
FianlimabFase 3En marcha, sin reclutarmar 2026 (real)

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT03188666), actualizada en nov 2022.